1. Home
  2. SGRP vs GLTO Comparison

SGRP vs GLTO Comparison

Compare SGRP & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SPAR Group Inc.

SGRP

SPAR Group Inc.

HOLD

Current Price

$0.86

Market Cap

27.3M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$29.45

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGRP
GLTO
Founded
1967
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.3M
23.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
SGRP
GLTO
Price
$0.86
$29.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
67.6K
519.8K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$147,130,000.00
N/A
Revenue This Year
$7.22
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.79
N/A
52 Week Low
$0.85
$2.01
52 Week High
$2.10
$33.60

Technical Indicators

Market Signals
Indicator
SGRP
GLTO
Relative Strength Index (RSI) 32.37 70.58
Support Level $0.85 $16.70
Resistance Level $0.92 $29.03
Average True Range (ATR) 0.05 2.60
MACD -0.00 0.64
Stochastic Oscillator 6.67 94.66

Price Performance

Historical Comparison
SGRP
GLTO

About SGRP SPAR Group Inc.

SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: